Expertise in
8
conditions

Ruifang An

No. 277 West Yanta Road, 
Xi'an, CN 
Expertise in
8
conditions
No. 277 West Yanta Road, 
Xi'an, CN 
OverviewLocationsClinical Research

Overview

Ruifang An practices in Xi'an, China. An is highly rated in 8 conditions, according to our data. Their top areas of expertise are Choriocarcinoma, Vulvovaginitis, Vaginal Yeast Infection, Ovarian Cancer, and Hysterectomy.

Their clinical research consists of co-authoring 74 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 277 West Yanta Road, Xi'an, 710061, China
Other Locations
No.277, Yanta Western Road, Xi'an, 710061, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: TQB2450, Anlotinib
Study Phase: Phase 2
View 1 Less Clinical Trial

74 Total Publications

DNMT1 reduces cisplatin sensitivity partially through downregulating FOXO3a in ovarian cancer cells.
DNMT1 reduces cisplatin sensitivity partially through downregulating FOXO3a in ovarian cancer cells.
Journal: Journal of chemotherapy (Florence, Italy)
Published: September 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find An's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile